PHIO net incomeQ3 2026-$4.16M
PHIO net income was -$4.16M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.39M a year earlier. For the full fiscal 2025 it was -$8.70M, compared with -$7.15M in fiscal 2024.
Phio Pharmaceuticals Corp. (PHIO) financials
For the twelve months ended Sep 30, 2026, Phio Pharmaceuticals Corp. reported -$14.67M of net income.
- Net income, TTM
- -$14.67M
- Free cash flow, TTM
- -$12.40M
- Cash
- $10.61M
- Market cap
- $9.3M
FY2016FY2020
FY2016FY2025
FY2016FY2025
PHIO revenue and earnings growth
PHIO free cash flowQ3 2026-$2.28M
PHIO free cash flow was -$2.28M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.09M a year earlier. For the full fiscal 2025 it was -$7.99M, compared with -$7.11M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $0 | $21.0K | $138.0K | $15.0K | $19.0K |
| Research and development | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M | $3.72M | $4.30M | $4.33M | $5.37M | $5.42M |
| Selling, general and admin | $4.60M | $3.74M | $4.37M | $4.45M | $4.63M | $5.08M | $4.71M | $3.18M | $4.01M | $3.62M |
| Operating income | -$9.22M | -$7.39M | -$10.82M | -$11.46M | -$13.51M | -$8.79M | -$8.99M | -$7.36M | -$14.06M | -$9.02M |
| Pre-tax income | - | - | - | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$14.07M | -$8.99M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.62M | $0 |
| Net income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$12.45M | -$8.99M |
| EPS, basic | -$1.45 | -$9.08 | -$46.76 | -$10.10 | -$149.16 | -$23.04 | -$231.96 | -$689.52 | -$3643.20 | -$10830.60 |
| EPS, diluted | - | -$9.08 | -$46.76 | -$10.10 | -$149.16 | -$23.04 | -$231.96 | -$689.52 | -$3643.20 | -$10830.60 |
| Diluted shares | - | 787,466 | 231,508 | 1.1M | 89,102.833 | 382,278.833 | 38,400.75 | 10,673.75 | 3,420.839 | 1,022.133 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.03M | $5.38M | $8.49M | $11.83M | $24.11M | $14.29M | $6.98M | $14.93M | $3.63M | $12.96M |
| Current assets | $21.48M | $5.74M | $9.32M | $12.45M | $24.73M | $15.16M | $7.30M | $15.15M | $3.83M | $13.11M |
| Total assets | $21.49M | $5.74M | $9.36M | $12.81M | $25.17M | $15.74M | $8.04M | $15.32M | $4.10M | $13.40M |
| Current liabilities | - | $1.01M | $1.63M | $1.94M | $3.07M | $2.20M | $1.88M | $1.74M | $2.27M | $2.54M |
| Long-term debt | - | - | - | - | $0 | $231.0K | $0 | - | - | - |
| Total debt | - | - | - | - | $0 | $231.0K | $0 | - | - | - |
| Total liabilities | $1.34M | $1.01M | $1.63M | $1.97M | $3.24M | $2.72M | $2.29M | $1.74M | - | - |
| Shareholders' equity | $20.15M | $4.72M | $7.73M | $10.84M | $21.93M | $13.02M | $5.75M | $13.58M | $1.83M | $10.86M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.98M | -$7.11M | -$10.75M | -$12.13M | -$11.86M | -$8.80M | -$8.64M | -$7.52M | -$9.51M | -$7.76M |
| Capital expenditures | $12.0K | $1.0K | $5.0K | $121.0K | $51.0K | $19.0K | $72.0K | $5.0K | $203.0K | $4.0K |
| Free cash flow | -$7.99M | -$7.11M | -$10.75M | -$12.25M | -$11.91M | -$8.82M | -$8.72M | -$7.53M | -$9.72M | -$7.76M |
| Investing cash flow | -$12.0K | $8.0K | -$5.0K | -$121.0K | -$51.0K | -$19.0K | -$72.0K | -$5.0K | -$103.0K | $5.35M |
| Financing cash flow | $23.64M | $4.00M | $7.41M | -$26.0K | $21.72M | $16.13M | $772.0K | $18.82M | $292.0K | $10.20M |
| Stock-based compensation | $481.0K | $147.0K | $303.0K | $414.0K | $480.0K | $136.0K | $300.0K | $282.0K | $314.0K | $756.0K |
| Depreciation and amortization | $3.0K | $2.0K | $56.0K | $71.0K | $75.0K | $72.0K | $67.0K | $81.0K | $70.0K | $53.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | -100.0% | -84.8% | 820.0% | -21.1% | -44.1% |
| Operating margin | - | - | - | - | - | - | -42795.2% | -5336.2% | -93746.7% | -47447.4% |
| Net margin | - | - | - | - | - | - | -42419.0% | -5333.3% | -83013.3% | -47336.8% |
| Free cash flow margin | - | - | - | - | - | - | -41509.5% | -5452.9% | -64780.0% | -40863.2% |
| Return on equity | -43.2% | -151.4% | -140.1% | -105.9% | -60.6% | -67.6% | -155.0% | -54.2% | -679.3% | -82.9% |
| Return on assets | -40.5% | -124.6% | -115.6% | -89.6% | -52.8% | -55.9% | -110.8% | -48.0% | -303.9% | -67.1% |
| Current ratio | - | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
| Debt to equity | - | - | - | - | 0.00 | 0.02 | 0.00 | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.06M | $3.08M | $2.79M | $1.48M | $1.18M | $1.07M | $886.0K | $985.0K | $644.0K | $866.0K | $1.15M | $1.01M |
| Selling, general and admin | $1.21M | $1.19M | $1.37M | $1.06M | $1.32M | $1.24M | $986.0K | $689.0K | $946.0K | $1.05M | $1.06M | $766.0K |
| Operating income | -$4.27M | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M | -$1.59M | -$1.91M | -$2.21M | -$1.90M |
| Interest expense | - | - | - | - | - | - | -$125.0K | - | - | - | -$53.0K | - |
| Net income | -$4.16M | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | -$1.77M | -$1.63M | -$1.52M | -$1.85M | -$2.15M | -$1.90M |
| EPS, basic | -$0.36 | -$0.36 | -$0.34 | - | -$0.44 | -$0.45 | -$0.41 | - | -$1.54 | -$3.62 | -$0.47 | - |
| EPS, diluted | - | - | - | - | - | -$0.45 | -$0.41 | - | -$1.54 | -$3.62 | -$0.47 | - |
| Diluted shares | - | - | - | - | - | 4.8M | 4.3M | - | 990,033 | 510,188 | 4.6M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.61M | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M | $5.39M | $4.70M | $6.47M | $8.49M |
| Current assets | $11.31M | $14.30M | $17.40M | $21.48M | $11.49M | $11.29M | $13.44M | $5.74M | $5.86M | $5.29M | $6.85M | $9.32M |
| Total assets | $11.32M | $14.31M | $17.41M | $21.49M | $11.51M | $11.30M | $13.44M | $5.74M | $5.87M | $5.30M | $6.85M | $9.36M |
| Current liabilities | - | - | - | - | - | $1.21M | $1.27M | $1.01M | $919.0K | $1.52M | $1.25M | $1.63M |
| Total liabilities | $2.70M | $1.71M | $950.0K | $1.34M | $1.67M | $1.21M | $1.27M | $1.01M | - | - | - | $1.63M |
| Shareholders' equity | $8.62M | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M | $4.95M | $3.77M | $5.60M | $7.73M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.08M | -$2.54M | -$1.27M | -$1.37M | -$1.95M | -$1.78M | -$2.01M | -$2.37M |
| Capital expenditures | $0 | $0 | $0 | $0 | $7.0K | $3.0K | $2.0K | $1.0K | $0 | $0 | $0 | $0 |
| Free cash flow | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.09M | -$2.54M | -$1.28M | -$1.37M | -$1.95M | -$1.78M | -$2.01M | -$2.37M |
| Investing cash flow | $0 | $0 | $3.0K | $0 | -$7.0K | -$3.0K | -$2.0K | $8.0K | $0 | $0 | $0 | $0 |
| Financing cash flow | -$107.0K | $0 | $0 | $12.40M | $2.02M | $40.0K | $9.17M | $1.35M | $2.65M | $0 | -$4.0K | $2.40M |
| Stock-based compensation | $285.0K | $278.0K | $318.0K | $274.0K | $113.0K | $51.0K | $43.0K | $48.0K | $52.0K | $15.0K | $32.0K | $9.0K |
| Depreciation and amortization | $2.0K | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 | $0 | $1.0K | $1.0K | $10.0K |
Key ratios
Source: XBRL data Phio Pharmaceuticals Corp. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported May 12, 2016; 1-for-10, first reported Mar 26, 2018; 1-for-55, first reported Mar 26, 2020; 1-for-12, first reported May 11, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PHIO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PHIO | - | - | -$14.67M | - | $9.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
PHIO FAQ
5 questionsIs PHIO profitable?
No. Phio Pharmaceuticals Corp. reported a net loss of $14.67M for the twelve months ended Sep 30, 2026.How much cash and debt does PHIO have?
Phio Pharmaceuticals Corp. reported $10.61M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PHIO free cash flow?
Phio Pharmaceuticals Corp. generated -$12.40M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$12.40M less capital expenditures.When did PHIO last report financial results?
The latest statements here come from Phio Pharmaceuticals Corp.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this PHIO financial data come from?
Quantisnow builds these statements from the structured XBRL data Phio Pharmaceuticals Corp. files with the SEC. It is provided for information only and is not investment advice.